# PROMUS PREMIER™ China Post-Approval Study

> **NCT03273023** · — · COMPLETED · sponsor: **Boston Scientific Corporation** · enrollment: 2059 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System

## Key facts

- **NCT ID:** NCT03273023
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-11
- **Primary completion:** 2020-12-28
- **Final completion:** 2025-10-03
- **Target enrollment:** 2059 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03273023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03273023, "PROMUS PREMIER™ China Post-Approval Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03273023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*